Samsung Electronics’ aspirations.... to find a new growth engine in biotechnology ...with their version of Rituxan called SAIT101.
Samsung and 15 other companies are eyeing the 6.5 billion Rituxan market, when patents come off in 2014-15, hoping to mix up their own versions of Rituxan.
The major use is for Rheumatoid Arthritis, CLL is just a footnote, but we will likely benefit from the competition.
UK trial of SAIT101
Some trials have been temporarily halted...
Thanks Chris - very interesting, as I have had RA for many years. The Rheumatologist said he wouldn't give me any "disease modifying drugs" now, as they would confuse things regarding my CLL and that when I have treatment for the CLL, then my RA will be helped.
I can't seem to make the Uk Clinical trials link work though.
Warm wishes
sparkler x
Ooppps...this blog truncates links when you cut and paste... here it is again.
clinicaltrialsregister.eu/c...
Rituxan works very well for RA, it is a huge market.
I'll try the link again Chris. Yes the Rheumatologist talked about Rituxan, shortly after my CLL dx.
Samsung to form a $300 million joint venture with Biogen to develop bio-pharmaceuticals.
Biogen makes Rituxan...
CLL Rituximab - first Rituxan Hycela Shot went well!
Obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan - Roche press release on CLL11 study
RITUXAN transfusion for CLL patient with ITP (Low platelets)?
Hurray, Three Cheers for Venclexta & Rituxan
